. 1 The effectiveness of antimuscarinic agents in the treatment of the overactive bladder (OAB) syndrome is thought to arise through blockade of bladder muscarinic receptors located on detrusor smooth muscle cells, as well as on nondetrusor structures. . 2 Muscarinic M 3 receptors are primarily responsible for detrusor contraction. Limited evidence exists to suggest that M 2 receptors may have a role in mediating indirect contractions and/or inhibition of detrusor relaxation. In addition, there is evidence that muscarinic receptors located in the urothelium/suburothelium and on afferent nerves may contribute to the pathophysiology of OAB. Blockade of these receptors may also contribute to the clinical efficacy of antimuscarinic agents. . 3 Although the role of muscarinic receptors in the bladder, other than M 3 receptors, remains unclear, their role in other body systems is becoming increasingly well established, with emerging evidence supporting a wide range of diverse functions. Blockade of these functions by muscarinic receptor antagonists can lead to similarly diverse adverse effects associated with antimuscarinic treatment, with the range of effects observed varying according to the different receptor subtypes affected. . 4 This review explores the evolving understanding of muscarinic receptor functions throughout the body, with particular focus on the bladder, gastrointestinal tract, eye, heart, brain and salivary glands, and the implications for drugs used to treat OAB. The key factors that might determine the ideal antimuscarinic drug for treatment of OAB are also discussed. Further research is needed to show whether the M 3 selective receptor antagonists have any advantage over less selective drugs, in leading to fewer adverse events.
Introduction
Antimuscarinic agents are commonly used to treat patients suffering from the overactive bladder (OAB) (Figure 1 (#fig1) ), given that the correlation between functional affinity in human isolated detrusor and recombinant receptor affinity across a range of muscarinic antagonists is greatest for the M 3 subtype. Further evidence to support the functional role of the M 3 subtype comes from studies in M 3 knockout mice. In bladder strips from such mice, 95% of the contraction induced by carbachol is mediated by M 3 receptors, as shown by a reduction in the maximal contractile response to only 5% of that seen in wild-type mice (Matsui et al., 2000 (#bib93) ). However, these mice have an almost normal cystometric pattern owing to the remaining purinergic activation mechanism (Igawa et al., 2004 (#bib77) ). The role of the M3 receptor in detrusor contraction. Acetylcholine (ACh), produced in the presynaptic terminal by the action of choline acetyl transferase (ChAT) on choline and acetyl coenzyme A (acetyl-CoA), is released by exocytosis. ACh is metabolized by acetyl cholinesterase (AChE) to release choline. Detrusor contraction is mediated by the binding of ACh on postjunctional membrane muscarinic M 3 receptors (M 3 ), resulting in activation of the contractile proteins within the detrusor muscle (Effects). Prejunctional M 2 and M 4 receptors inhibit, whereas prejunctional M 1 receptors facilitate the release of ACh. The M 2 receptor also appears to have an indirect functional role in detrusor contractility, and possibly a minor direct effect, but the mechanism remains unclear. Atropine inhibits contraction by blockade of muscarinic receptors. The functional role of the large M 2 receptor population in detrusor muscle remains unclear. An investigation using M 2 , M 3 and M 2 /M 3 double knockout mice revealed that that the M 2 receptor may have a role in indirectly mediating bladder contractions by enhancing the contractile response to M 3 receptor activation, and that minor M 2 receptor-mediated contractions may also occur (Ehlert et al., 2005 (#bib53) ). The authors of another rodent study suggest that the stimulation of M 2 receptors may serve to inhibit sympathetically (i.e. beta-adrenoceptor) mediated relaxation, which in turn leads to more efficient emptying of the bladder (Hegde et al., 1997 (#bib73) ). A functional role for M 2 receptors in bladder function may emerge in certain disease states, as observed in studies of outflow obstruction in rats (Braverman et al., 1998 (#bib24) ; Braverman & Ruggieri, 2003 (#bib25) ) and neurogenic human bladder (Pontari et al., 2004 (#bib103) ). In denervated rat bladder, for example, there is an increase in M 2 receptor density (with a corresponding increase in the M 2 : M 3 ratio), with functional affinity of muscarinic antagonists more closely resembling their affinity for M 2 than for M 3 receptors (Braverman et al., 1998 (#bib24) ). However, the functional affinity of the M 3 selective antagonist 4-DAMP did not differ in normal and obstructed rat bladder (Krichevsky et al., 1999 (#bib86) ). Sympathetic modulation of the human bladder via M 2 receptors may also be inferred as noradrenergic innervation, albeit scarce, has been demonstrated in human bladder body and increases in the outflow region (see Gosling et al., 1999 (#bib67) ).
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Two studies presented at the American Urological Association meeting in 2004 reported that the M 3 receptor was responsible for mediating the direct contractile response in human detrusor muscle tissue taken from patients with neurogenic and idiopathic detrusor overactivity (DO) and those with normal bladder function (Stevens et al., 2004a (#bib126) , 2004b (#bib127) ). Furthermore, no changes in receptor subtype contribution to detrusor contractions in the disease state were observed. The concentration-response curves to carbachol indicated that muscarinic receptor-mediated function was enhanced in the neurogenic and idiopathic DO tissue compared with normal bladder tissue in vitro. The presence of the M 3 receptor selective antagonist 4-DAMP reduced the contractile response to carbachol in the normal bladder and in the neurogenic and idiopathic DO, whereas the M 2 receptor selective antagonist, methoctramine, was less effective in all tissues. However, the study did not show any significant differences from unity in the Schild slopes for either antagonist (Stevens et al., 2004b (#bib127) ). As such, an indirect role of M 2 receptors in mediating contractile responses cannot be discounted.
Findings from in vitro research using human and guinea-pig bladder tissue have led to the proposal that a network of interstitial cellssimilar to the interstitial cells of Cajal in the gut (myofibroblasts) -within the suburothelial layer may augment and coordinate autonomous detrusor activity (see Fry et It is clear that the control of normal and pathological bladder function and the functional role of muscarinic receptors is highly complex. It remains unknown as to whether the efficacy of antimuscarinic agents in the treatment of OAB is specific to an effect on M 3 receptors within the detrusor muscle, or whether actions at other receptor sites such as sensory nerves or urothelium/suburothelium contribute to the therapeutic effect.
The salivary glands
The parasympathetic nervous system plays a pivotal role in the production of saliva by serous and mucous cells of the acinar structures in salivary glands (see Baum, 1993 (#bib18) ) and by serous cells in the parotid glands. Human and rodent studies show that both M 1 and M 3 receptors are present in the salivary glands, whereas the parotid glands express predominantly M 3 receptors (Culp et ; the robustness of these findings may be inferred from the finding that these effects were observed across different modes of induction of salivation (via electrical stimulation of the parasympathetic nervous system or stimulated by oxotremorine or pilocarpine). Thus, salivation is predominantly mediated by the M 3 receptors that are involved in the control of both high-and lowviscosity secretions and saliva volume, whereas the M 1 subtype is involved in the control of high-viscosity lubrication. This has been illustrated by preclinical studies in rats and cats which demonstrated that selective antagonism of M 3 receptors inhibits, but does not eliminate, salivary responses to carbachol or electrical stimulation (Gillberg et al., 1998 (#bib61) ; Ikeda et al., 2002 (#bib78) ).
Although salivation is primarily mediated by M 3 receptors, the functional importance of multiple muscarinic receptor subtypes in the quantity and quality of salivary secretion is highlighted by the fact that agonist-induced salivation (using oxotremorine, pilocarpine or isoproterenol) is depressed in the M 3 knockout mouse, yet the buccal cavity remains lubricated (Matsui et In the clinical context, some studies have shown that M 3 -selective and nonselective muscarinic receptor antagonists (with activity at both M 1 and M 3 receptors) appear to reduce salivation in similar proportions of patients (Diokno et al., 2003 (#bib46) ; Haab et  al., 2004 (#bib69) ; Armstrong et al., 2005 (#bib15) ). In contrast, in a crossover study of 65 patients with OAB comparing darifenacin with oxybutynin, treatment with oxybutynin immediate release (IR) 5 mg three times daily was associated with significantly greater reductions (P<0.05) in salivary flow than darifenacin controlled release (CR) (15 mg once daily or 30 mg once daily) (Chapple & Abrams, 2005 (#bib32) ). It is possible that, compared with antagonism of both receptor subtypes, sparing the M 1 receptors in the salivary glands may help to maintain enough lubrication to alleviate the sensation and severity of dry mouth. This is supported by low discontinuation rates owing to dry mouth (<3%) during darifenacin treatment, based on a pooled analysis of three darifenacin studies (Chapple et al., 2005 (#bib31) ).
The gastrointestinal tract
Although gut smooth muscle has been shown to contain all five muscarinic receptor subtypes in differing proportions in guinea-pigs ( Numerous other signaling mechanisms, mediated by a variety of neurotransmitters within the enteric nervous system, also appear to play a major role in physiological control of gastrointestinal function. Serotonergic (5-HT) receptors have been shown to be important in the control of gastrointestinal motility and sensitivity. For example, the 5-HT 4 receptor subtype mediates excitatory effects (Gershon, 2003 (#bib59) ) and directly influences gastrointestinal secretion. Other signalling mechanisms implicated in the control of gastrointestinal function include substance P and neurokinin (NK) A acting at NK 1 and NK 2 receptors, and the inhibition of nitric oxide release. The complex interplay between these mechanisms helps explain why M 3 knockout mice have no overt gastrointestinal problems (Matsui et al., 2000 (#bib93) ).
As with the bladder, many gaps in knowledge still exist regarding the functional role of muscarinic receptors and the contribution of specific subtypes within the gastrointestinal tract. These include the role of muscarinic receptors expressed by interstitial cells of Cajal and enteric neurons, the role of M 4 and M 5 receptors on smooth muscle and the mechanisms of long-term compensation for muscarinic deprivation. In the clinical setting, constipation following muscarinic antagonist therapy is often reported as one of the classic muscarinic adverse events. This is to be expected given the need to target the M 3 receptor to achieve clinical efficacy in OAB, and the role of this receptor in the complex mechanisms involved in gastrointestinal transit. In a pooled analysis of fixed dose clinical studies with the M 3 selective receptor antagonist darifenacin, an increase was observed in the reported incidence of constipation compared with placebo (14.8 and 21.3% all-causality incidence for darifenacin CR 7.5 and 15 mg once daily, respectively, compared with 6.2% for placebo) (Chapple et al., 2005 (#bib31) ). Although the incidence of constipation appears to be higher with darifenacin than for other antimuscarinics, a clinical comparison of darifenacin and the nonselective muscarinic receptor antagonist tolterodine IR showed that that the two agents were associated with similar incidences of new-onset laxative use for constipation and discontinuations owing to constipation (Thomas et al., 2005 (#bib129) ). However, further detailed studies are needed to investigate the comparative clinical effects of M 3 selective and nonselective muscarinic receptor antagonists on the gastrointestinal tract.
The brain
Muscarinic receptors in the brain activate a multitude of signaling pathways important for the modulation of neuronal excitability, synaptic plasticity and feedback regulation of ACh release. All five muscarinic receptor subtypes are expressed in the brain (see Volpicelli & Levey, 2004 (#bib137) ). M 1 receptors, for example, are most abundant in the neocortex, hippocampus and neostriatum, whereas M 2 receptors are located throughout the brain. In contrast, levels of M 3 receptors are low whereas M 4 receptors are abundant in the neostriatum, and M 5 receptors have been localized to the projection neurons of substantia nigra, pars compacta, ventral tegmental area and the hippocampus (Table 1 (#tbl1) ). Central muscarinic receptors are involved in higher cognitive processes such as learning and memory. It is generally accepted that M 1 receptors play an important functional role in this regard. Indeed, antagonism of central M 1 receptors with intrahippocampal pirenzepine impaired spatial memory in rat models (Messer et al., 1990 (#bib94) ). Also, mice lacking the M 1 receptor exhibit defects in a number of cognitive processes (Anagnostaras et al., 2003 (#bib3) ), and M 1 receptor agonists reverse learning and spatial memory impairment in animal models of Alzheimer's disease (see Fisher et al., 2003 (#bib56) ). In clinical studies, an M 1 /M 4 receptor agonist has been reported to improve cognition in patients with Alzheimer's disease, as measured on the Clinician's Interview Based Impression of Change, although treatment was associated with a high incidence of systemic side effects (Bodick et al., 1997 (#bib21) ). Central M 1 antagonism may therefore give rise to cognitive dysfunction and other central nervous system (CNS)-related adverse events. These effects are becoming increasingly associated with antimuscarinic agents with a relatively high affinity for this receptor ( It is also important to note that antagonism of muscarinic M 1 and M 2 receptors in the brain is dependent not only on a drug's affinity for these receptors, but also on the drug concentration within the CNS. This is determined by the balance between drug penetration through the blood-brain barrier (BBB) and efflux. Thus, the molecular size, polarity and lipophilicity, and specificity for the Pglycoprotein efflux pump may influence the risk of adverse CNS effects with antimuscarinic drugs. However, the drug levels in the CNS may change in situations where the BBB becomes 'leaky' following damage (e.g. under conditions of stress, advanced age or presence of comorbid conditions such as diabetes or multiple sclerosis) (see Mechanisms implicated in increased BBB permeability include epithelial shrinkage accompanied by opening of tight junctions and dilation of the blood vessels resulting in increased blood flow and enhanced transport, as shown in a rat model (Abdel-Rahman et al., 2002 (#bib1) ). Other mechanisms could include enhanced pinocytotic activity, which is seen with increasing age (Pakulski et al., 2000 (#bib99) ). Consequently, all antimuscarinic receptor antagonists, irrespective of their physicochemical properties, have the potential to cross the BBB, although the level of affinity/serum concentration needed to affect muscarinic receptors mediating cognitive function requires investigation. However, available evidence suggests that a key issue regarding the potential for minimizing any cognitive adverse events with antimuscarinic agents would be to spare the M 1 receptor.
The eye
The findings of immunoprecipitation studies show that all five muscarinic receptor subtypes exist within the human eye, of which the ., 2000 (#bib41) ). A functional role for M 4 receptors in the eye remains to be determined. Of note, animal studies have shown that M 1 , M 2 and M 3 receptors can mediate activation of conjunctival goblet cells -the primary source of mucins in the tear film (Kanno et al., 2003 (#bib82) ).
The propensity for an antimuscarinic agent to cause ocular events will depend upon a number of factors. Consideration should be given to the serum levels necessary to affect structures within the eye, and the specific affinities of the muscarinic receptors present with a given serum level of drug. As such, although ocular events may be seen with both M 3 and M 5 receptor antagonism, blurred vision is uncommon with the selective M 3 receptor antagonist darifenacin, with one comparative study reporting no episodes of blurred vision in contrast to a 3% rate with the less selective agent oxybutynin (Zinner et al., 2005 (#bib151) ).
Similar to the brain, the potential for adverse effects in the eye with a particular antimuscarinic may not only depend on the selectivity of the drug but also its physical characteristics, potential to cross the blood-retina barrier, which regulates permeation of substances from the blood to the retina (see Duvvuri et al., 2003 (#bib50) ), and affinity for potential mechanisms regulating efflux.
The heart
Stimulation of muscarinic receptors within the mammalian heart, specifically the M 2 subtype (see Hulme et ) ). Whether this finding extends to human tissue remains to be determined, and data from functional studies using the human coronary artery are awaited.
In summary, available data indicate a prominent role of M 2 receptors in cardiac function. Further work is required to elucidate the role of other muscarinic receptor subtypes in the heart and how this may be altered in disease states.
Determining the ideal antimuscarinic drug for treatment of OAB
The third International Consultation on Incontinence Committee on Drug Therapy reviewed the considerable data supporting the clinical efficacy and safety of antimuscarinic drugs for the treatment of OAB. Following full development programs, darifenacin and solifenacin are the latest agents to enter the market, which includes oxybutynin, propiverine, tolterodine and trospium. There are other historically important but infrequently used drugs with antimuscarinic actions including imipramine (a tricyclic antidepressant with central and peripheral effects), flavoxate (a tertiary amine with calcium antagonistic activity in the bladder), dicyclomine (an antimuscarinic with calcium antagonistic properties) and propantheline (a quaternary amine with anticholinergic activity in the bladder and gastrointestinal tract) (see Andersson et al., 2005 (#bib9) ). However, the latter drugs will not be further discussed in this review.
When identifying the features of the ideal antimuscarinic drug for treatment of OAB, it is important to consider a number of factors. These agents differ with respect to structural characteristics (e.g. trospium is a quaternary ammonium compound, others are tertiary amines), pharmacokinetic profile and mechanism(s) of action (in addition to antimuscarinic action, drugs may also have a calcium channel blocking property). Furthermore, sparing or affecting a particular muscarinic receptor has the potential to be beneficial in terms of tolerability/safety.
Formerly, an ideal antimuscarinic was one that could block the efferent impulses that caused detrusor contraction, without having dose-
studies between drugs will be needed to resolve the question: 'Which is the best available drug?' However, this question may be difficult to answer until we have more reliable instruments to assess both the symptoms of OAB, such as urgency, and the adverse effects, such as bowel disturbance.
Secondary mechanisms of antimuscarinic drug action
In theory, drugs that have actions in addition to antagonism of muscarinic receptors -such as nonspecified 'direct muscle relaxant effects' (e.g. as attributed to oxybutynin), calcium channel blocking or potassium channel opening properties -could increase effectiveness. Table 2 ( Clearly, such secondary actions can also result in undesirable effects. For example, terodiline -a drug widely perceived by patients and clinicians alike as an effective antimuscarinic -was withdrawn by the regulatory authorities in 1991 owing to its cardiac adverse event profile. This drug possessed calcium channel blocking activity, and induced a specific cardiac arrhythmia known as 'Torsades de Pointes' (see Roden, 2004 (#bib113) ). By contrast, a clinical study demonstrated that the M 3 receptor selective muscarinic antagonist, darifenacin, does not prolong the QT interval and is therefore not expected to cause any harmful effects on cardiac repolarisation (Serra et al., 2005 (#bib115) ).
Dosing and pharmacokinetic considerations
Patient compliance with medication is influenced by a number of factors including dosing schedules (Richter et al., 2003 (#bib112) ). Compliance decreases with increasing number of daily doses, with a pronounced effect noted when more than two doses per day are prescribed (Claxton et al., 2001 (#bib38) ). If the assumption is made that once-daily dosing is optimal, then a single dose needs to provide clinically significant efficacy over a period as close as possible to 24 h. For some patients, treatment given when needed might be preferable, perhaps for 'special occasions' such as socializing. Here, a faster-onset shorter-acting preparation may be useful, although it is important that rapid efficacy is not achieved at the penalty of an unacceptable increase in side effects. ., 2004 (#bib117) ), solifenacin is an outlier in relation to the other drugs. In theory, a longer duration of action following a single dose may be beneficial in smoothing out serum peaks that are believed to increase the prevalence of side effects. However, if the duration of action exceeds 24 h following a single daily dose, then drug accumulation could be an issue. Also, should side effects occur, the patient may have to wait longer before these effects subside. A further downside of a long half-life may be that time to reach steady state is likely to be longer. ). There is some evidence, for each drug, that once-daily dosing of the ER preparation leads to a modest increase in efficacy and a decrease in side effects (Table 3 ( 2005 (#bib109) ). Of particular note are the high levels of protein binding reported for most antimuscarinic agents, which would suggest that levels of circulating free drug would be too low to exert pharmacodynamic effect. Despite this, the efficacy of these antimuscarinics is well established. Clearly, therefore, other properties must also be important, and these may include factors such as steady-state levels of receptor occupancy, data on which are not readily available, and the role of active metabolites. The plasma concentration profiles of the active metabolites of tolterodine (4-hydroxymethyltolterodine) and oxybutynin (N-desethyloxybutynin) are shown in Figures 2 (#fig2) and 3(a) (#fig3) , respectively. Although these clearly exert a pharmacodynamic effect, it is not clear what proportion of total effect may be attributed to the active metabolite versus parent molecule. 
Receptor activity of antimuscarinic agents
The receptor activity of antimuscarinics can be expressed in different ways, including pharmacologically derived characteristics (Table 5 (#tbl5) ) (Napier & Gupta, 2002 (#bib95) ) and clinical uroselectivity. In general, animal models have been used to demonstrate uroselectivity, with studies focusing on how beneficial effects on the bladder predominate over unwanted effects on saliva production (dry mouth) and cardiac effects. Such models demonstrate a wide variation in apparent uroselectivity between drugs (i.e. depending on the model chosen, a selected antimuscarinic may be more uroselective than the others). Nevertheless, such models have been used for the selection of drugs for further development. However, there have been few investigations of uroselectivity performed in humans. One study by Chapple (2001) (#bib30) investigated tolterodine ER (6 mg) and oxybutynin ER (5, 15 and 25 mg) in 16 healthy male volunteers. Tolterodine ER 6 mg produced an increase in bladder capacity comparable with that expected with an oxybutynin ER dose of approximately 20 mg, and a reduction in salivation comparable to that expected with an oxybutynin ER dose of approximately 10 mg. If it were accepted that the M 3 receptor is the only receptor that is important when treating OAB, then it would be expected that a drug that spares other muscarinic receptors would give rise to an optimal tolerability and safety profile. However, the adverse event of constipation associated with the antimuscarinic class of agents might also still be expected.
Establishing and comparing risk:benefit profiles
Adverse event profiling of each drug may shed light on the relationships between beneficial effects and adverse events for each drug. ., 2003 (#bib71) ). However, comparison of drug profiles using existing clinical study data is difficult due to the lack of standardization of inclusion/exclusion criteria, measurement instruments and the drug dosages used. At present, therefore, it is difficult to draw firm conclusions as to which type of antimuscarinic does, or will, offer the best benefit-to-risk ratio. The recommendations of the International Continence Society's Clinical Trials Standardisation Committee and use of the International Consultation Incontinence modular questionnaire may be helpful. These may enable trials to be conducted that will allow easier comparison between antimuscarinic drugs by making available a standard basic protocol, together with valid instruments to assess outcomes. Nevertheless, a major difficulty will always be how to compare the drugs at similar clinically relevant doses.
Etiology of DO
Finally, the etiology of DO is another factor that impacts the efficacy of antimuscarinic therapy. Although it is well established that the contractions of the detrusor muscle are in response to the cholinergic stimulation of muscarinic receptors located in the bladder, the exact etiology of DO is largely unknown. The pathophysiology of DO may be neurogenic, myogenic or a combination of both. Neurogenic pathophysiology may possibly involve reduced suprapontine inhibition, damaged axonal paths through the spinal cord, increased afferent input from the lower urinary tract, loss of peripheral inhibition and/or enhanced excitatory neurotransmission in the micturition reflex pathway (see de Groat, 1997 (#bib43) ). In contrast, myogenic pathophysiology has been postulated to develop following local denervation of bladder smooth muscle leading to increased excitability and easier signal transmissibility between myocytes, thus stimulating the propagation of coordinated contractions (see Turner & Brading, 1997 (#bib134) ) or micromotions.
Data from guinea-pig studies has also linked DO with inappropriate activation or modulation of autonomous activity via suburothelial interstitial cells, resulting in pathological localized contractions and 'sensory urgency' (Gillespie, 2004a (#bib62) ). There is also evidence that ACh may be released or leak from postganglionic parasympathetic neurons or from non-neuronal sources during bladder filling, with subsequent micromotions in the detrusor causing an increase in afferent stimulation (see Andersson, 2004 (#bib7) ).
Conclusions
It is well established that muscarinic receptor subtypes are widely distributed throughout the human body, each type having a specific functional and physiological role in each tissue. This distribution of muscarinic receptor subtypes can represent a considerable therapeutic challenge when trying to target receptors specific to an organ system. For example, both in normal bladders and in OAB, detrusor muscle contractions are primarily mediated by stimulation of bladder muscarinic M 3 receptors; blockade of M 3 receptors can alleviate the symptoms of OAB, although the classic antimuscarinic adverse events of constipation and dry mouth remain. In addition, as evidence is emerging for an indirect role of M 2 receptors in detrusor contractility, the potential benefits and risks of M 2 receptor antagonism should be further investigated.
Thus, there are a number of important factors that need to be considered when identifying the features of the ideal antimuscarinic drug for treatment of OAB. In the case of OAB, clinical uroselectivity is important (i.e. targeting the bladder) -unwanted effects such as cognitive impairment and blurred vision can only occur if the drug crosses the BBB and blood-retina barrier, respectively; if the drug has a chemical structure which imparts a limited ability to cross these barriers then receptor selectivity in those end organs becomes less of an issue. It remains to be established whether antagonist activity at the M 3 receptor subtype, together with blockade of M 2 receptors or a secondary nonmuscarinic effect (e.g. direct muscle relaxant effect via calcium channel antagonism or potassium channel activation), will increase effectiveness in treating OAB. However, it will be important to establish the risk:benefit ratio for such agents with secondary mechanisms of action. Furthermore, considering the age of patients receiving OAB treatments, it would be preferable to identify those agents that are free of CNS sedation and impairment, and that do not add to the CNS anticholinergic burden.
When considering the pharmacodynamic and pharmacokinetic properties of an antimuscarinic agent, it is important that the pharmacokinetics of the drug (or the formulation of the drug) are such that dosing is once (or no more than twice) daily, as this imparts greatest patient compliance to the dosing schedule.
Antimuscarinic agents relatively selective for the M 3 receptor subtype are now available for the treatment of OAB. Current evidence suggests that efficacy observed in pivotal phase III studies with M 3 receptor selective agents is comparable to existing less selective agents. Whether M 3 relative receptor selectivity can reduce the adverse events and safety concerns theoretically attributed to the untargeted blockade of muscarinic receptors has yet to be determined. Limited data are available that directly compare the efficacy and safety profiles of drugs with differing muscarinic receptor subtype selectivity. In this regard further data are needed. 
